Have you and your family had your flu shot? It's more important than ever this year! Schedule via MyChart or call for an appointment in SF, the East Bay or San Mateo.

Jonathan Chou

MD PhD

Genitourinary oncologist
Cancer researcher, amateur bassoonist and pianist

About me

Dr. Jonathan Chou cares for patients with cancers affecting the genital and urinary organs, including prostate, bladder, kidney and testicular cancers. Rather than taking a one-size-fits-all approach, he applies precision medicine techniques – which take into account an individual's genes, lifestyle and other factors – to treatment, with targeted therapies and immunotherapy among the components in his oncology arsenal.

Chou is a physician-scientist, a doctor particularly focused on medical research. His areas of research include developing more precise ways to treat cancer. He studies molecular subtypes of cancer and uses genome-editing technology to engineer cell models in the lab, seeking to understand how specific mutations affect cancer properties. He also uses genetic and drug screening to find new ways of killing cancer cells, and incorporates patient-derived tumor xenografts (models in which cells from a patient’s tumor are implanted in an animal) to investigate drug resistance.

Chou earned his medical degree and a doctorate in biomedical sciences from UCSF. He also completed a residency in internal medicine and a fellowship in oncology at UCSF.

In his free time, Chou loves trying new bakeries and restaurants around San Francisco. He and his wife enjoy going to the beach with their young daughter and their Aussiedoodle.

  • Education

    UCSF, PhD, Biomedical Sciences, 2012

    UCSF School of Medicine, MD, 2014

  • Residencies

    UCSF, Internal Medicine, 2016

  • Fellowships

    UCSF, Oncology, 2020

As a cancer survivor of more than 15 years, I am dedicated to improving patient care and outcomes through cutting-edge research and kindness.

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Selected research

Decorative Caduceus

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

The primary objective is overall response rate (ORR) of patients with metastatic CRPC. Response will be defined as a 50% decline in PSA (prostate specific antigen) from baseline as determined by PCWG3 criteria.

Recruiting

Share